{
    "clinical_study": {
        "@rank": "124328", 
        "arm_group": [
            {
                "arm_group_label": "Vehicle", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "M518101", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to evaluate the pharmacokinetics and safety of M518101 in male and female\n      plaque psoriasis patients."
        }, 
        "brief_title": "Study to Evaluate the Pharmacokinetics and the Safety of M518101 in Plaque Psoriasis Patients", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Psoriasis", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Who are able and willing to give signed informed consent\n\n          -  Who are male or females aged 18 years or older with plaque psoriasis confirmed by the\n             Investigator.\n\n          -  Who have \u226520% of body surface area (BSA) afflicted with plaques\n\n          -  Who are neither pregnant nor breast-feeding, nor plan to become pregnant during the\n             study.\n\n        Exclusion Criteria:\n\n          -  Who have a history of allergy to vitamin D3 derivative preparations or a history of\n             relevant drug hypersensitivity.\n\n          -  BMI > 32.0 kg/m2\n\n          -  Who are pregnant or lactating.\n\n          -  Who have any renal or hepatic insufficiency, or clinically significant cardiac, renal\n             or hepatic disease.\n\n          -  Who are not deemed eligible as determined by medical history, physical examination or\n             clinical laboratory safety tests.\n\n          -  Who have clinically relevant history or presence of any disease or surgical history\n             other than psoriasis which is likely to affect the conduct of the study.\n\n          -  Whose serum calcium levels exceed the upper limit of reference range\n\n          -  Who have used any investigational medicinal product and/or participated in any\n             clinical study within 60 days of randomization.\n\n          -  Who have taken any durg with known effects on calcium metabolism within 30days of\n             randomization\n\n          -  Who have been treated with any drug with a known risk of QT prolongation within\n             30days of randomization."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01844973", 
            "org_study_id": "M518101-US05"
        }, 
        "intervention": [
            {
                "arm_group_label": "M518101", 
                "description": "Proper quantity twice a day", 
                "intervention_name": "M518101", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "description": "Proper quantity twice a day", 
                "intervention_name": "Vehicle", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "August 15, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tustin", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92780"
                }, 
                "name": "Orenge County Research Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Area under the plasma concentration versus time curve (AUC) of M5181", 
                "safety_issue": "Yes", 
                "time_frame": "0, 1, 2, 4, 6, 9 12h after dosing"
            }, 
            {
                "measure": "Peak Plasma concentration (Cmax) of M5181", 
                "safety_issue": "Yes", 
                "time_frame": "0, 1, 2, 4, 6, 9 12h after dosing"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01844973"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Maruho North America Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Maruho North America Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}